Senesco's Technology Reduces Inflammatory Response in Mouse Model.

NEW BRUNSWICK, N.J. -- Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) announced today that the Company's eukaryotic translation initiation Factor 5A-1 ("Factor 5A-1" or "eIF5A-1") gene technology reduced inflammation and inhibited apoptosis in mouse experiments conducted by W. Michael Scheld, M.D., at the University of Virginia School of Medicine.

In these experiments, mice were pre-treated with Senesco's small interfering RNA ("siRNA") against Factor 5A-1 and then challenged with LPS, which causes a classic systemic inflammatory response. The Factor 5A-1 pre-treated mice had significantly reduced blood levels of multiple pro-inflammatory cytokines, including TNF-alpha and interleukins 1, 2, 6, 12, MIP-1alpha, and IFN-gamma. Also of interest was that the cytokine IL-10, a down-regulator of pro-inflammatory cytokines, was unaffected by Factor 5A-1, further enforcing that Factor 5A-1 selectively recruits mRNAs for apoptosis and inflammation.

These data, in conjunction with the Company's previously reported data (Senesco press release April 29, 2005) in which siRNA-treated mice had increased survival rates in the presence of lethal doses of LPS, indicate that siRNA to Factor 5A-1 protects against premature cell death caused by inflammation. Further, the previously mentioned survival data was presented at an Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting where it was selected for an award in the category of therapeutics. The award given to the LPS survival abstract was one of only six out of approximately 2700 abstracts submitted for consideration.

Dr. Scheld commented, "The down regulation of multiple pro-inflammatory cytokines in response to this siRNA administration is striking and encouraging for further studies. It will be of interest to study the cytokine response in more depth, especially when the siRNA is given after LPS."

About Senesco Technologies, Inc.

Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if its technology is applicable in human medicine. Accelerating apoptosis may have applications to the development of cancer treatments. Delaying apoptosis may have applications to certain diseases such as glaucoma, ischemia and arthritis, among others. Senesco takes its name from the scientific term for the aging of plant cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. In addition to its human health research programs, the Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.